Evidence map›Paper›PMID 32659767›Full record

ReviewNephron2020

Harnessing Endogenous T-Regulatory Cells in Acute Kidney Injury.

Rahul Sharma

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nephron, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Rahul SharmaCenter for Immunity, Inflammation and Regenerative Medicine, Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA, rs3wn@hscmail.mcc.virginia.edu.
University of Virginia · US

Funding

The TREX1 Pathway in Autoimmune DiseaseR01AI116725 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PERRINO, FRED W · 2016 to 2020
$1.9M
Regulatory T Cells in Acute Kidney InjuryR01DK104963 · NIDDK · UNIVERSITY OF VIRGINIA · PI SHARMA, RAHUL · 2016 to 2020
$1.8M
Targeting Treg for Therapy of Lupus GlomerulonephritisR01DK105833 · NIDDK · UNIVERSITY OF VIRGINIA · PI FU, SHU MAN, SHARMA, RAHUL · 2016 to 2019
$1.4M
The University of Virginia Kidney Technology Development Research Education Program (VA K-TUTOR)R25DK124918 · NIDDK · UNIVERSITY OF VIRGINIA · PI GUILFORD, WILLIAM H, OKUSA, MARK DOUGLAS · 2020 to 2024
$699k
Circulating Renal-Protective Mediators in Cardiac Surgery PatientsR21DK112105 · NIDDK · UNIVERSITY OF VIRGINIA · PI LYNCH, KEVIN R., ROSNER, MITCHELL H. · 2017 to 2018
$443k
NIAID NIH HHS R01 AI116725NIDDK NIH HHS R01 DK104963NIDDK NIH HHS R01 DK105833NIDDK NIH HHS R21 DK112105NIDDK NIH HHS R25 DK124918
6 · The paper itself

Abstract

Acute kidney injury (AKI) affects 20-50% of hospitalized and intensive care patients, with a sizable proportion progressing to ESRD or death (https://www.kidney.org/atoz/content/AcuteKidneyInjury). Since inflammation contributes to the pathogenesis of AKI, studies on T-regulatory cells (Tregs), which suppress inflammation are important. Here, we highlight advances that utilize Tregs for intervention in AKI and were presented at the 25th International Conference on Advances in Critical Care Nephrology and UAB/UCSD O'Brien Center AKI & CRRT 2020.

Indexed as

Acute Kidney InjuryHumansT-Lymphocytes, RegulatoryAcute kidney injuryInflammationInterleukin-2Interleukin-33RegenerationT-regulatory cells

Identifiers

PMID32659767
PMCPMC7708413
OpenAlexW3042606385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.